Skip to main content
SpringerLink
Log in

Méthodologie des biopsies dans l’œsophage de Barrett

Biopsy methodology in Barrett’s œsophagus

  • Published:
Acta Endoscopica

Résumé

L’œsophage de Barrett se définit comme le remplacement de l’épithélium pavimenteux pluristratifié du bas œsophage par une muqueuse cylindrique métaplasique. C’est sur la muqueuse de type spécialisé que se développent les foyers de dysplasie et de cancérisation: raison pour laquelle il est impératif de les mettre en évidence et de bien les localiser pour assurer un suivi correct du patient par une standardisation des prélèvements. La réalisation d’une cartographie des prélèvements associée à la pratique de colorationin vivo améliore le rendement diagnostique et facilite le suivi des patients. Des examens immunohistochimiques réalisés sur les biopsies de certains cas peuvent aider à sélectionner des patients à risque.

Summary

Barrett’s œsophagus is defined as the replacement of the pluristratified squamous epithelium of the lower esophagus by a metaplastic columnar mucosa. It is the site where areas of dysplasiacarcinoma develop. It is imperative to identify and localise these through the standardisation of sampling to ensure proper patient followup. Systematic mapping and in vivostaining improves diagnostic yield and facilitates patient followup. Immunohistochemical examination can help to select patients at risk.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Références

  1. PAULL A., TRIER J.S., DALTON M.D. — The histologic spectrum of Barrett’s esophagus.N. Engl. J. Med., 1976,295, 476–480.

    PubMed  CAS  Google Scholar 

  2. SPECHLER S.J., GOYAL R.K. — Barrett’s esophagus.N. Engl. I. Med., 1986, 315–362.

  3. MAINGUET P., JOURET A. — Surveillance de l’endobrachycesophage.Acta Endoscopica, 1992,22, 511–517.

    Article  Google Scholar 

  4. JOURET A., MAINGUET P., AKELE M.Th. — Systematic mapping and histo-endoscopy study of columnar lined epithelium in extended Barrett’s esophagus.Acta Gastroent. Belg., 1993,56, 1 C16.

    Google Scholar 

  5. GEBOES K., Van EYCKEN P. — The diagnosis of dysplasia and malignancy in Barrett’s esophagus.Histopathology, 2000,37, 99–107.

    Article  PubMed  CAS  Google Scholar 

  6. CADIOT G. — Endoscopic et surveillance de la muqueuse de Barrett.Castroenterol. Clin. Biol., 2003,27, 689–691.

    Google Scholar 

  7. SPECHLER S.J. — Barrett’s esophagus.N. Engl. J. Med., 2002,346, 836–842.

    Article  PubMed  Google Scholar 

  8. RIDDELL R.H., GOLDMAN H., RANSOHOFF D.F., APPELMAN H.D., FENOGLIO C.M., HAGGITT R.C. — Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications.Hum. Pathol., 1983,414, 931–968.

    Article  Google Scholar 

  9. SAMPLINER R.E. and the Practice Parameters Committee of the American College of Gastroenterology. — Practice guidelines on the diagnosis, surveillance and therapy of Barrett’s esophagus.Am. J. Gastroent., 1998,93, 1028–1032 and Update guidelinesAm. J. Gastroent., 2002,97, 1888–1895.

    Article  PubMed  CAS  Google Scholar 

  10. BUTTAR N.S., WANG K.K., SEBO T.J., RIEHLE D.M., KRISNADATH K.K., LUTZKE L.S. — Extent of high grade dysplasia in Barrett’s esophagus correlates with risk of adenocarcinoma.Gastroenterology, 2001,120, 1630–1639.

    Article  PubMed  CAS  Google Scholar 

  11. BIAN Y.S., OWTERHELD M.C., BOSMAN F.T., BENHATTAR J., FONTOLLIET C. — P53 gene mutation and protein accumulation during neoplastic progression in Barrett’s esophagus.Mod. Pathol, 2001,14, 397–403.

    Article  PubMed  CAS  Google Scholar 

  12. GIMÉNEZ A., DE HARO L.M., PARRILLA P., BERMEJO J., PEREZ-GUILLERMO M., ORTIZ M.A. — Immunohistochemical detection of P53 protein could improve the management of some patients with Barrett esophagus and mild histologic alterations.Arch. Pathol. Lab. Med., 1999,123, 1260–1263.

    PubMed  Google Scholar 

  13. WESTON A.P., BANERJEE S.K., SHARMA P., TRAN T.M, RICHARDS R., CHERIAN R. — P53 protein overexpression in low grade dysplasia (LGD) in Barrett’s esophagus: immunohistochemical marker predictive of progression.Am. J. Gastroent., 2001,96, 1321–1323.

    Article  Google Scholar 

  14. ROUX-LECLERCQ N., TURLIN B., SUTHERLAND F., HERESBACH N., LAUNOIS B., CAMPION J.P., RAMEE M.P. — Analysis of KI67, p53, and Bcl2 expression in the dysplasia-carcinoma sequence of Barrett’s esophagus.Oncol. Rep., 1999,6, 877–882.

    Google Scholar 

  15. FLEJOU J.P., POTET F., MUZEAU F. — Overexpression of p 53 protein in Barrett’s syndrome with malignant transformation.J. Clin. Pathol, 1993,46, 330–333.

    Article  PubMed  CAS  Google Scholar 

  16. GLEESON C.M., SLOAN J.M., MCMANUS D.T. — Comparison of P53 and DNA content abnormalities in adenocarcinoma of the esophagus and gastric cardia.Br. J. Cancer, 1998,77, 277–286.

    PubMed  CAS  Google Scholar 

  17. HALL P.A., WOODMAN A.C., CAMPBELL S.J., SHEPERD N.A. — Expression of the p53 homologue p63alpha and DeltaNp63alpha in the neoplastic sequence of Barrett’s oesophagus: correlation with morphology and p53.Gut, 2001,49, 618–623.

    Article  PubMed  CAS  Google Scholar 

  18. REID B.J., HAGGITT R.C., RUBIN C.E., ROTH G., SURAWICZ C.M., Van BELLE G.et al.— Observer variation in the diagnosis of dysplasia in Barrett’s esophagus.Hum. Pathol., 1988,19, 166–178.

    Article  PubMed  CAS  Google Scholar 

  19. SAGAN C., FLEJOU J.F., DIEBOLD M.D., POTET F., LE BODIC M.F. — Reproductiblé des critères histologiques de dysplasie sur muqueuse de Barrett.Gastroenterol. Clin. Biol., 1994,18, D31-D34.

    PubMed  CAS  Google Scholar 

  20. ORMSBY A.H., VAEZI M.F., RICHTER J.E., GOLDBLUM J.R. — Cytokeratin immunoreactivity patterns in the diagnosis of short-segment Barrett’s oesophagus.Gastroenterology, 2000,119, 683–69.

    Article  PubMed  CAS  Google Scholar 

  21. COUVELARD A., CAUVIN J.M., GOLDAIN D., ROTEN-BERG A., ROBASZKIEWICZ M., FLEJOU J.F. — Cytokeratine immunoreactivity of intestinal metaplasia at normal oesophagogastric junction indicates its aetiology.Gut, 2001,49, 761–766.

    Article  PubMed  CAS  Google Scholar 

  22. DEBONGNIES J.C., MACCHI H., MAINGUET P. — Schéma planimétrique destiné à la surveillance de l’œsophage à haut risque.Acta Endoscopica, 1981,11, 353–356.

    Article  Google Scholar 

  23. ROBEY S.S., HAMILTON S.R., GUPTA P.K., EROZAN Y.S. — Diagnostic value of cytopathology in Barrett esophagus and associated carcinoma.Am. J. Clin. Pathol., 1988,89, 493–498.

    PubMed  CAS  Google Scholar 

  24. GEISINGER K.R., TEOT L.A., RICHTER J.E. — A comparative cytopathologic and histologie study of atypia, dysplasia, and adenocarcinoma in Barrett’s esophagus.Cancer, 1992, 69–78.

  25. FENNERTY M.B. — La chromoscopie dans le diagnostic et la surveillance de l’œsophage de Barrett.Acta Endoscopica, 2001,52, 151–159.

    Article  Google Scholar 

  26. CANTO M.I., SETRAKIAN S., PETRAS R.E., BLADES E., CHAK A., SIVAK M.V. — Méthylène blue selectively stains intestinal metaplasia in Barrett’s esophagus.Gastrointest. Endosc., 1996,44, 1–7.

    Article  PubMed  CAS  Google Scholar 

  27. CANTO M.I.F., SETRAKAIN S., WILLIS J.E. — Méthylène blue staining of dysplastic and non dysplastic Barrett’s esophagus: anin vivo andex vivo study.Endoscopy, 2001,33, 391–400.

    Article  PubMed  CAS  Google Scholar 

  28. CANTO M.I.F., SETRAKIAN S., WILLIS J., CHAK A., PETRAS R., POWE N., SIVAK M.V. — Méthylène blue — directed biopsies improve detection of intestinal metaplasia and dysplasia in Barrett’s esophagus.Gastrointest. Endosc., 2000,57, 5–10.

    Google Scholar 

  29. GIOVANNINI M. — De la dysplasie à la dysphagie.Gastroenterol. Clin. Biol., 2003,27, B143-B145.

    PubMed  Google Scholar 

  30. WO J.M., RAY M.B., MAYFIELD-STOKES S., AL-SABBAGH G., GEBRAIL F., SLO S. — Comparison of méthylène blue-directed biopsies and conventional biopsies in the detection of intestinal mataplasia and dysplasia in Barrett’s esophagus: a preliminary study.Gastrointest. Endosc., 2001,54, 409–413.

    Article  Google Scholar 

  31. GUELRUD M., HERRERA I. ESSENFELD H.et al. — Enhanced magnification endoscopy: a new technique to identify specialized metaplasia in Barrett’s esophagus.Gastrointest. Endosc., 2001,55, 559–565.

    Article  Google Scholar 

  32. EGGER K., WERNER M., MEINING A., OTT R., ALLES-CHER H.D., HOFLER H. — Biopsy surveillance is still necessary in patients with Barrett’s esophagus despite new endoscopic imaging techniques.Gut, 2003,52, 18–23.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d’Anatomie Pathologique, CHR, Tournai, Belgique

    A. Jouret

  2. Faculté de Médecine de Lille, France

    J. S. Delmotte

Authors
  1. A. Jouret
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. S. Delmotte
    View author publications

    You can also search for this author in PubMed Google Scholar

About this article

Cite this article

Jouret, A., Delmotte, J.S. Méthodologie des biopsies dans l’œsophage de Barrett. Acta Endosc 33, 727–731 (2003). https://doi.org/10.1007/BF03002611

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03002611

Mots-clés

Key-words

Search

Navigation